Zobrazeno 1 - 5
of 5
pro vyhledávání: '"TAKASHI IMAJIMA"'
Autor:
Tomoko Kodama, Takashi Imajima, Mototsugu Shimokawa, Taiga Otsuka, Masahiro Kawahira, Junichi Nakazawa, Takeshi Hori, Taro Shibuki, Shiho Arima, Akio Ido, Keisuke Miwa, Yoshinobu Okabe, Futa Koga, Yujiro Ueda, Yoshihito Kubotsu, Hozumi Shimokawa, Shigeyuki Takeshita, Kazuo Nishikawa, Azusa Komori, Satoshi Otsu, Ayumu Hosokawa, Tatsunori Sakai, Kenji Sakai, Hisanobu Oda, Machiko Kawahira, Shuji Arita, Takuya Honda, Hiroki Taguchi, Kengo Tsuneyoshi, Yasunori Kawaguchi, Toshihiro Fujita, Takahiro Sakae, Tsuyoshi Shirakawa, Toshihiko Mizuta, Kenji Mitsugi
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract Nanoliposomal irinotecan with fluorouracil and folinic acid (NFF) is a standard regimen after gemcitabine-based therapy for patients with unresectable or recurrent pancreatic cancer. However, there are limited clinical data on its efficacy a
Externí odkaz:
https://doaj.org/article/eebc9af936314345b048057f5416b5fd
Autor:
TAKASHI IMAJIMA, TSUYOSHI SHIRAKAWA, YASUYUKI OHTSU, HITOMI UCHIHASHI, TAIGA OTSUKA, KOICHI AKASHI, EISHI BABA, KENJI MITSUGI
Publikováno v:
Cancer Diagnosis & Prognosis; Jul/Aug2024, Vol. 4 Issue 4, p503-509, 7p
Autor:
Tomoyasu Yoshihiro, Hiroshi Ariyama, Kyoko Yamaguchi, Takashi Imajima, Satoru Yamaga, Kenji Tsuchihashi, Taichi Isobe, Hitoshi Kusaba, Koichi Akashi, Eishi Baba
Publikováno v:
Cancer science. 113(12)
Microtubule targeting agents (MTAs) such as taxanes are broadly used for the treatment of patients with cancer. Although MTAs are not effective for treatment of colorectal cancer (CRC), preclinical studies suggest that a subset of patients with CRC,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6763ae4ecc7660c396463133734089af
https://pubmed.ncbi.nlm.nih.gov/36053154
https://pubmed.ncbi.nlm.nih.gov/36053154
Autor:
Takashi Imajima, Koki Uehara, Yudai Shinohara, Kenta Nio, Taiga Otsuka, Go Shirakawa, Kenji Mitsugi
Publikováno v:
Annals of Oncology. 33:S520
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1365fe0a1c16d09181c9cd3e0e1b8a14
https://doi.org/10.1016/j.annonc.2022.05.260
https://doi.org/10.1016/j.annonc.2022.05.260
Autor:
Yoshihiro Matsumoto, Hiroshi Ariyama, Makoto Endo, Tomoyasu Yoshihiro, Koichi Akashi, Hirofumi Ohmura, Kohei Arimizu, Eishi Baba, Kyoko Yamaguchi, Mamoru Ito, Fumiyasu Hanamura, Nokitaka Setsu, Kenro Tanoue, Takashi Imajima, Yudai Shinohara, Yasuharu Nakashima, Satoru Yamaga, Taichi Isobe, Toshifumi Fujiwara, Hitoshi Kusaba, Kenji Tsuchihashi
Publikováno v:
Scientific Reports
Doxorubicin is a first-line therapy for patients with unresectable advanced soft tissue sarcoma (STS). However, because of cardiotoxicities, it is not used for patients with cardiac problems. Eribulin has exhibited efficacy for advanced STS in second
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2a128f6d79a6d1d23f86247b94f9586
https://doi.org/10.1038/s41598-020-77898-y
https://doi.org/10.1038/s41598-020-77898-y